# CFI-402257

Source: https://onco.cc/drugs/cfi-402257/  
OnCo record `cfi-402257` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CFI-402257 is an experimental small molecule from Treadwell Therapeutics, in phase 2 trials for HR-positive / HER2-negative breast cancer, HER2-negative breast cancer and advanced solid tumours.

## Summary

CFI-402257 is a small molecule from Treadwell Therapeutics. A potent and selective small-molecule inhibitor of TTK, tested alone in solid tumours and with fulvestrant or paclitaxel in breast cancer. Its furthest stage is phase 2, for HR-positive / HER2-negative breast cancer, HER2-negative breast cancer and advanced solid tumours. ClinicalTrials.gov registers it in 4 studies linked below. NCT05251714 (Treadwell, phase 1/2) and NCT03568422 (CCTG IND.236) active, not recruiting; NCT05601440 (CCTG platform, phase 2) recruiting (registry, checked 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: CFI-402257
- Modality: Small molecule
- Mechanism: A potent and selective small-molecule inhibitor of TTK, tested alone in solid tumours and with fulvestrant or paclitaxel in breast cancer.

## Sources

- Treadwell Therapeutics: treadwelltx.com: https://treadwelltx.com/pipeline/
- Treadwell Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05251714
- ClinicalTrials.gov: trials of CFI-402257: https://clinicaltrials.gov/search?intr=CFI-402257

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [MPS1 (TTK)](https://onco.cc/targets/ttk/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)
- trials: [A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct02792465/), [CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer](https://onco.cc/trials/nct03568422/), [CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer](https://onco.cc/trials/nct05251714/), [Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer](https://onco.cc/trials/nct05601440/)

---
JSON: https://onco.cc/api/v1/entities/cfi-402257.json